New interview in Scrip! Read more about our novel approach to CNS drug development and our focus on repurposing existing drugs with the aid of digital biomarkers.
Read the interview here.
For further information, contact:
Jenny Barnett, CEO
Richard Hayhurst/Janet Joy
E: Richard@rhapr.eu or firstname.lastname@example.org
Tel: +44 7711 821527
Notes to Editors:
About Monument Therapeutics
Monument Therapeutics is bringing stratified medicine to neuroscience drug development. The company uses proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds.
For further information visit www.monumenttx.com